Update shared on08 Aug 2025
Fair value Increased 5.10%Analysts have raised their consensus revenue growth forecast for Outset Medical from 11.8% to 12.6% per annum, offsetting a higher discount rate, and resulting in an increased fair value price target from $24.50 to $25.75.
What's in the News
- Outset Medical raised its 2025 revenue guidance to $122 million-$126 million from $115 million-$125 million.
- The company was added to numerous Russell indexes, increasing index fund inclusion and market visibility.
- Renee Gaeta was appointed as Chief Financial Officer, bringing experience from Shockwave Medical, Eko Health, and Establishment Labs.
- Outset Medical reiterated full-year 2025 revenue guidance at $115 million-$125 million prior to raising it.
Valuation Changes
Summary of Valuation Changes for Outset Medical
- The Consensus Analyst Price Target has risen from $24.50 to $25.75.
- The Discount Rate for Outset Medical has risen from 7.72% to 8.34%.
- The Consensus Revenue Growth forecasts for Outset Medical has risen from 11.8% per annum to 12.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.